Sana Biotechnology, Inc. (SANA)

Sana Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	180.89	137.35	182.87	253.03	126.95	81.81
Short-Term Investments	134.03	71.68	247.2	297.97	253.46	58.95
Cash & Cash Equivalents	314.91	209.03	430.06	551	380.41	140.76
Cash Growth	-11.39%	-51.40%	-21.95%	44.84%	170.25%	347.62%
Other Current Assets	6.35	4.49	14.37	7.11	4.06	3.5
Total Current Assets	321.26	213.52	444.44	558.1	384.47	144.26
Property, Plant & Equipment	153.21	145.59	159.4	161.78	109.94	68.81
Long-Term Investments	0	0	14.46	204.7	33.73	0
Goodwill and Intangibles	199.82	199.82	199.82	199.82	199.82	199.82
Other Long-Term Assets	7.08	6.37	4.6	5	2.33	2.3
Total Long-Term Assets	360.11	351.78	378.28	571.31	345.83	270.93
Total Assets	681.38	565.3	822.72	1,129	730.3	415.19
Accounts Payable	6.1	4.11	2.86	2.22	2.25	0
Current Debt	13.17	13.2	12.39	9.16	3.71	1.34
Other Current Liabilities	33.64	47.18	96.25	87.86	25.49	17.98
Total Current Liabilities	52.9	64.49	111.5	99.24	31.45	19.32
Long-Term Debt	92.92	90.9	95.86	101.78	68.2	46.36
Other Long-Term Liabilities	160.41	122.41	116.04	199.89	198.94	74.69
Total Long-Term Liabilities	253.33	213.31	211.9	301.67	267.13	121.05
Total Liabilities	306.24	277.79	323.41	400.91	298.58	140.38
Total Debt	106.09	104.1	108.25	110.94	71.91	47.7
Debt Growth	-7.35%	-3.84%	-2.42%	54.28%	50.75%	-
Retained Earnings	-1,445.57	-1,338.09	-1,054.84	-785.36	-429.43	-144.13
Comprehensive Income	-0.02	-0.06	-4.33	-1.37	0.03	0.03
Shareholders' Equity	375.14	287.51	499.32	728.5	-421.18	-142.54
Net Cash / Debt	208.83	104.93	321.81	440.05	308.5	93.06
Net Cash / Debt Growth	-13.32%	-67.39%	-26.87%	42.64%	231.51%	195.93%
Net Cash Per Share	0.96	0.54	1.71	2.64	23.71	18.98
Working Capital	268.36	149.03	332.93	458.87	353.02	124.94
Book Value Per Share	1.73	1.48	2.65	4.38	-32.36	-29.07

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).